Recent Price Movement and Market Context
On 24 Nov 2025, Bal Pharma’s stock recorded an intraday low of Rs.75, representing a decline of 2.52% on the day. This movement contributed to a cumulative loss of 6.56% over the past six trading days. The stock’s performance notably lagged behind its sector peers, underperforming by 2.39% relative to the Pharmaceuticals & Biotechnology sector benchmark.
Bal Pharma’s current trading levels are below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. This contrasts with the broader market, where the Sensex opened 88.12 points higher and was trading at 85,450.59, up 0.26% on the day. The Sensex is also approaching its 52-week high of 85,801.70 and has recorded a 2.68% gain over the past three weeks, supported by strong performances from mega-cap stocks.
Long-Term Performance and Valuation Metrics
Over the last year, Bal Pharma’s stock has delivered a return of -44.61%, significantly underperforming the Sensex, which posted an 8.02% gain during the same period. The stock’s 52-week high was Rs.133.20, highlighting the extent of the decline to the current low of Rs.75.
From a valuation standpoint, the company’s Return on Capital Employed (ROCE) averaged 9.24% over the long term, indicating modest capital efficiency. Net sales have grown at an annual rate of 8.78% over the past five years, reflecting subdued growth relative to sector peers. The company’s ability to service debt is constrained, with a Debt to EBITDA ratio of 4.53 times, suggesting elevated leverage levels.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Results and Profitability Trends
Bal Pharma has reported negative results for four consecutive quarters, with Profit Before Tax excluding other income (PBT LESS OI) at Rs. -0.40 crore, reflecting a decline of 125.64%. The half-year ROCE stood at 8.99%, while the operating profit to interest coverage ratio was recorded at 1.48 times, indicating limited cushion to meet interest obligations.
These figures underscore challenges in both near-term profitability and long-term financial health. The company’s performance has been below par not only in recent quarters but also over extended periods, with returns underperforming the BSE500 index across one-year, three-year, and three-month horizons.
Valuation and Peer Comparison
Despite the subdued financial performance, Bal Pharma’s valuation metrics suggest some degree of attractiveness. The company’s ROCE of 7.8 and an Enterprise Value to Capital Employed ratio of 1.2 indicate that the stock is trading at a discount relative to its historical peer valuations. However, profit levels have declined by 11% over the past year, aligning with the downward trend in share price.
Considering Bal Pharma ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Shareholding and Sector Positioning
Bal Pharma operates within the Pharmaceuticals & Biotechnology industry and sector, where it faces intense competition and evolving market dynamics. The majority shareholding is held by promoters, which may influence strategic decisions and capital allocation.
While the broader market indices, such as the Sensex, are exhibiting bullish trends supported by mega-cap stocks, Bal Pharma’s stock continues to reflect pressures from its financial and operational metrics. The divergence between the company’s stock performance and the overall market highlights sector-specific and company-specific factors impacting investor sentiment.
Summary of Key Metrics
To summarise, Bal Pharma’s stock has reached a 52-week low of Rs.75 after a sustained period of decline. The stock’s underperformance is evident in its six-day losing streak and a year-to-date return of -44.61%. Financial indicators such as ROCE, debt servicing capacity, and recent quarterly results point to ongoing challenges. Despite some valuation appeal relative to peers, the company’s profit contraction and leverage remain areas of concern.
Investors and market participants will continue to monitor Bal Pharma’s financial disclosures and sector developments as the stock navigates this low price territory.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
